SCHEMBL23147752

SCHEMBL23147752

COC(=O)c1cc2cc(OC)cnc2n1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 3/20 0.47
NOD1 Q9Y239 3/20 0.47
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 2/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
PKM P14618 2/20 0.39
CCR6 P51684 1/20 0.39
PTGS2 P35354 1/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
CXCR2 P25025 1/20 0.39
AGTR1 P30556 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1683455 0.86 KDM4E (0.44) NOD1KMT2AMAPTKDM4EL3MBTL1
SCHEMBL23148046 0.85 NOD1 (0.48) NOD2NOD1KDM4EL3MBTL1LMNA
SCHEMBL30877293 0.85 NOD1 (0.43) NOD2NOD1KDM4EL3MBTL1LMNA
SCHEMBL23147626 0.81 CYP11B1 (0.44) NOD2NOD1KMT2APTGDR2PTGS2
SCHEMBL23147751 0.81 NOD1 (0.45) NOD2NOD1KMT2AMAPTL3MBTL1
SCHEMBL29813550 0.81 NOD1 (0.45) NOD2NOD1KMT2AMAPTL3MBTL1
SCHEMBL23147551 0.81 NOD1 (0.47) NOD2NOD1KMT2AMAPTKDM4E
SCHEMBL5716675 0.78 HDAC3 (0.43) KMT2AMAPTL3MBTL1LMNAMEN1
SCHEMBL2927020 0.77 PTGS2 (0.42) NOD2NOD1KMT2AMAPTKDM4E
SCHEMBL2924501 0.76 MAPT (0.42) NOD2NOD1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2023-01-05 US disclosed
EP-4034108-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS The Global Alliance for TB Drug Development, Inc. (US) 2022-08-03 EP disclosed
WO-2021062316-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2021-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS AZI2, AADAC, TPMT NOD2 1119/4885NOD1 1969/4885KMT2A 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.